A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL).

  • Fleming, Shaun Alan, (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusNot started

Keywords

  • Acute lymphoblastic leukaemia (ALL)
  • Malignant Haematology
  • Clinical trial
  • Acute lymphoblastic leukaemia (ALL)
  • Malignant Haematology
  • Clinical trial
  • Acute lymphoblastic leukaemia (ALL)
  • Malignant Haematology
  • Clinical trial